Logo image of KA

KINETA INC (KA) Stock Fundamental Analysis

USA - NASDAQ:KA - US49461C1027 - Common Stock

0.5746 USD
-0.25 (-30.69%)
Last: 9/18/2024, 8:11:30 PM
0.5995 USD
+0.02 (+4.33%)
After Hours: 9/18/2024, 8:11:30 PM
Fundamental Rating

0

Overall KA gets a fundamental rating of 0 out of 10. We evaluated KA against 531 industry peers in the Biotechnology industry. KA has a bad profitability rating. Also its financial health evaluation is rather negative. KA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KA had negative earnings in the past year.
In the past year KA has reported a negative cash flow from operations.
In the past 5 years KA always reported negative net income.
In the past 5 years KA always reported negative operating cash flow.
KA Yearly Net Income VS EBIT VS OCF VS FCFKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

KA's Return On Assets of -1492.21% is on the low side compared to the rest of the industry. KA is outperformed by 99.65% of its industry peers.
Industry RankSector Rank
ROA -1492.21%
ROE N/A
ROIC N/A
ROA(3y)-188.12%
ROA(5y)-135.68%
ROE(3y)-699.02%
ROE(5y)-456.44%
ROIC(3y)N/A
ROIC(5y)N/A
KA Yearly ROA, ROE, ROICKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

1.3 Margins

KA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KA Yearly Profit, Operating, Gross MarginsKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

KA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KA has more shares outstanding
KA has more shares outstanding than it did 5 years ago.
KA has a worse debt/assets ratio than last year.
KA Yearly Shares OutstandingKA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
KA Yearly Total Debt VS Total AssetsKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -225.92, we must say that KA is in the distress zone and has some risk of bankruptcy.
KA has a worse Altman-Z score (-225.92) than 98.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -225.92
ROIC/WACCN/A
WACC10.5%
KA Yearly LT Debt VS Equity VS FCFKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

KA has a Current Ratio of 0.14. This is a bad value and indicates that KA is not financially healthy enough and could expect problems in meeting its short term obligations.
KA has a Current ratio of 0.14. This is amonst the worse of the industry: KA underperforms 97.72% of its industry peers.
A Quick Ratio of 0.14 indicates that KA may have some problems paying its short term obligations.
The Quick ratio of KA (0.14) is worse than 97.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14
KA Yearly Current Assets VS Current LiabilitesKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.24% over the past year.
The Revenue for KA has decreased by -100.00% in the past year. This is quite bad
The Revenue has been growing by 13.89% on average over the past years. This is quite good.
EPS 1Y (TTM)68.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-598.43%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-7.61%
Revenue growth 5Y13.89%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 3.59% on average over the next years.
KA is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -41.42% yearly.
EPS Next Y3.18%
EPS Next 2Y3.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
KA Yearly Revenue VS EstimatesKA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
KA Yearly EPS VS EstimatesKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 -100 -200 -300 -400

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KA Price Earnings VS Forward Price EarningsKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KA Per share dataKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.59%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KINETA INC

NASDAQ:KA (9/18/2024, 8:11:30 PM)

After market: 0.5995 +0.02 (+4.33%)

0.5746

-0.25 (-30.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-09 2024-08-09/amc
Earnings (Next)11-01 2024-11-01/amc
Inst Owners0.31%
Inst Owner Change-99.99%
Ins Owners8.53%
Ins Owner Change0%
Market Cap7.04M
Revenue(TTM)N/A
Net Income(TTM)-20.88M
Analysts84.44
Price Target13.77 (2296.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS-0.66
TBVpS-0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1492.21%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.12%
ROA(5y)-135.68%
ROE(3y)-699.02%
ROE(5y)-456.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z -225.92
F-Score2
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)40.74%
Cap/Depr(5y)31.08%
Cap/Sales(3y)1.78%
Cap/Sales(5y)1.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-598.43%
EPS Next Y3.18%
EPS Next 2Y3.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-7.61%
Revenue growth 5Y13.89%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y68.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.37%
OCF growth 3YN/A
OCF growth 5YN/A

KINETA INC / KA FAQ

What is the fundamental rating for KA stock?

ChartMill assigns a fundamental rating of 0 / 10 to KA.


Can you provide the valuation status for KINETA INC?

ChartMill assigns a valuation rating of 0 / 10 to KINETA INC (KA). This can be considered as Overvalued.


Can you provide the profitability details for KINETA INC?

KINETA INC (KA) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for KA stock?

The Earnings per Share (EPS) of KINETA INC (KA) is expected to grow by 3.18% in the next year.